Nature Milestones on Alzheimer’s disease
Don’t miss out on this year’s Nature Milestones issue dedicated to Alzheimer’s disease. It’s packed with valuable insights, and there’s still time for you to catch up!
The landscape of Alzheimer’s disease therapy is evolving, thanks to the groundbreaking FDA approval of amyloid-β-targeting monoclonal antibodies. These first-ever disease-modifying therapies have ushered in a new era of hope for millions living with Alzheimer’s disease.
With over 50 million individuals globally affected by Alzheimer’s, the need for innovative solutions has never been more urgent. Since Alois Alzheimer’s first identified the disease in 1906, the quest to understand and combat this debilitating condition has only intensified. The journey from initial discovery to the development of transformative therapies has shaped today’s research environment, and the momentum is accelerating. Read the full article here>>
This Nature Milestones issue was produced with financial support from Eisai.
If you would like to sponsor a future Nature Milestones issue and drive meaningful change in the fight against Alzheimer’s or other key discoveries in the research field, contact our team!
About Nature Milestones:
Nature Milestones are published in Nature and on nature.com, highlighting key discoveries that have shaped different scientific fields.
They enable the wider recognition of classic findings, that are often recognized only by those in the field.
Content includes a timeline of key events, historical commentaries that have been commissioned and/or written by the editors, key papers, short research highlights on recently published papers, videos, and animations.
Nature Milestones offers sponsors a unique opportunity to cement their legacy of having been an active participant in the development of a given field over a period of time.
